Ascletis Announces Further Expansion of Ritonavir Oral Tablet Production Capacity to 530 Million Tablets Per Year
- Sunday, March 13, 2022, 7:13
- PR Newswire
- Add a comment
HANGZHOU, China and SHAOXING, China, March 13, 2022 /PRNewswire/ — Ascletis Pharma Inc. (Ascletis, HKEX: 1672) today announces that it has further expanded its ritonavir oral tablet production capacity to approximately 530 million tablets per year, to meet the potential escalation in the…